No connection

Search Results

ABBV vs PAVM

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
PAVM
PAVmed Inc.
BEARISH
Price
$9.11
Market Cap
$57.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ABBV
163.63
PAVM
--
Forward P/E
ABBV
15.42
PAVM
-3.32
P/B Ratio
ABBV
-146.66
PAVM
0.91
P/S Ratio
ABBV
6.5
PAVM
810.32
EV/EBITDA
ABBV
15.27
PAVM
-3.78

Profitability

Gross Margin
ABBV
71.46%
PAVM
-207.04%
Operating Margin
ABBV
35.5%
PAVM
-13082.7%
Profit Margin
ABBV
4.0%
PAVM
564.79%
ROE
ABBV
137.96%
PAVM
-32.34%
ROA
ABBV
9.59%
PAVM
-39.23%

Growth

Revenue Growth
ABBV
9.1%
PAVM
420.0%
Earnings Growth
ABBV
-88.7%
PAVM
--

Financial Health

Debt/Equity
ABBV
--
PAVM
0.6
Current Ratio
ABBV
0.72
PAVM
0.17
Quick Ratio
ABBV
0.47
PAVM
0.13

Dividends

Dividend Yield
ABBV
3.05%
PAVM
--
Payout Ratio
ABBV
490.15%
PAVM
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
PAVM BEARISH

PAVM exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9 and a catastrophic Current Ratio of 0.17, indicating a severe liquidity crisis. While revenue growth is nominally high (420%), the operational efficiency is non-existent with an operating margin of -13,082.69% and negative gross margins. There is a profound disconnect between the fundamental collapse (99.5% 5-year price decline) and the optimistic analyst target price of $40.50. The company is currently operating in a state of extreme financial fragility with no evidence of sustainable profitability.

Strengths
Significant year-over-year revenue growth (420%)
Price/Book ratio (0.91) suggests the stock is trading near its accounting book value
Recent earnings surprises have been positive relative to very low analyst expectations
Risks
Severe liquidity risk with a Current Ratio of 0.17 (cannot cover short-term obligations)
Extreme operational inefficiency evidenced by -13,082% operating margin
Negative gross margins indicate the cost of goods exceeds the selling price

Compare Another Pair

ABBV vs PAVM: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and PAVmed Inc. (PAVM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile